LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 12, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ: JUNO) securities between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”). Juno investors have until September 12, 2016 to file a lead plaintiff motion.
According to the Complaint, Juno materially misled investors by failing to disclose the May 2016 death of a patient in the Company’s Phase 2 trial of product candidate JCAR015. These omissions caused Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death. Then, following the death of two other patients in June and July, the U.S. Food and Drug Administration issued a clinical hold on the study, and Juno disclosed the patients’ deaths.
If you purchased or otherwise acquired Juno shares during the Class Period, you may move the Court no later than September 12, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.